Roche Diagnostics' Test Helps Doctors Determine Appropriate Pain-Relief Treatment for Nursing Mothers
Posted on: Friday, 17 August 2007, 21:04 CDT
INDIANAPOLIS, Aug. 17 /PRNewswire/ -- Nursing mothers can be tested with Roche Diagnostics' AmpliChip CYP450 Test to help their doctors determine whether they are ultra-rapid metabolizers of codeine.
The Food & Drug Administration issued a Public Health Advisory on Friday warning nursing mothers about the potential negative effects of codeine while nursing. The advisory is posted at http://www.fda.gov/cder/drug/advisory/codeine.htm.
Roche Diagnostics is the only company that makes an FDA-cleared test for determining a patients' CYP2D6 genotype, which helps a doctor predict how patients will metabolize certain drugs, including codeine.
The AmpliChip test analyzes variations in two genes -- CYP2D6 and CYP2C19 -- that play a primary role in the metabolism of some drugs used to treat severe depression, schizophrenia, bi-polar disorder, cardiovascular disease treated with beta-blockers, attention deficit/hyperactivity disorder (ADHD) and others.
Knowledge of these gene variations can be used to help individualize drug treatment through selection of the more appropriate drugs and adjustment of dosages. These measures have the potential to improve patient outcome by reducing adverse drug reactions and improving drug efficacy.
For a list of laboratories offering AmpliChip CYP450 Test, go to http://amplichip.us/.
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our U.S. website at http://www.roche-diagnostics.us/.
All trademarks used or mentioned in this release are legally protected by law.
For further information please contact: Lori McLaughlin Corporate Communication Roche Diagnostics Corporation, Indianapolis, Ind. Phone: 317-521-3112 lori.mclaughlin@roche.com
Roche Diagnostics
CONTACT: Lori McLaughlin, Corporate Communication of Roche DiagnosticsCorporation, +1-317-521-3112, lori.mclaughlin@roche.com
Web site: http://www.roche.com/http://www.roche-diagnostics.us/http://www.fda.gov/cder/drug/advisory/codeine.htmhttp://amplichip.us/
Source: PRNewswire
Related Articles
- Fujirebio Diagnostics and Roche Diagnostics Sign Agreement for New Ovarian Cancer Test
- Roche Diagnostics, a World Leader in HIV Monitoring Tests, and ARK Diagnostics, Inc. Sign Letter of Intent to Commercialize ARK's HIV Drug Monitoring Products
- Roche Diagnostics' HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
- Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
- Roche Diagnostics Announces Successful Resolution of Urgent Medical Device Correction Of CoaguChek PT Test Strips Used in Anticoagulation Monitoring
- Roche Diagnostics Submits West Nile Virus Blood Screening Test to FDA
- Roche Diagnostics Submits Hepatitis C Viral Load Monitoring Test to FDA
- New Blood Test for Management of Osteoporosis Cleared By the FDA; Roche Diagnostics' Test Aids Physicians and Patients in Monitoring Disease
- Roche Diagnostics' Dr. Lazarus Commits to Improving HIV Testing
 |
 |
User Comments (0)
RSS Feeds